Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Blood (2024) 144 (Supplement 1): 338.

https://doi.org/10.1182/blood-2024-199868

Published: 2024

Journal Articles

Tumor Microenvironment Differences between Diagnostic and Relapsed Classic Hodgkin Lymphoma Revealed By Single Cell Transcriptome Sequencing

Yifan Yin, Tomohiro Aoki, Shinya Rai, Aixiang Jiang, Alexander Xu, Luke O'Brien, Jan Delabie, Lauren Camille Chong, Stacy Hung, Akil Merchant, David W. Scott, Kerry J. Savage, Christian Steidl

Blood (2024) 144 (Supplement 1): 646.

https://doi.org/10.1182/blood-2024-209760

Published: 2024

Journal Articles

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

Blood (2024) 144 (Supplement 1): 469.

https://doi.org/10.1182/blood-2024-197938

Published: 2024

Journal Articles

CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 855.

https://doi.org/10.1182/blood-2024-199981

Published: 2024

Journal Articles

Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

Blood (2024) 144 (Supplement 1): 2966.

https://doi.org/10.1182/blood-2024-199227

Published: 2024

Journal Articles

A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis

Blood (2024) 144 (Supplement 1): 4475.

https://doi.org/10.1182/blood-2024-192949

Published: 2024

Journal Articles

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Blood (2023) 142 (Supplement 1): 177.

https://doi.org/10.1182/blood-2023-186810

Published: 2023

Journal Articles

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 172.

https://doi.org/10.1182/blood-2023-174139

Published: 2023

Journal Articles

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

Blood (2023) 141 (16): 1971–1981.

https://doi.org/10.1182/blood.2022017734

Published: 2023

Includes: Supplemental data

Journal Articles

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

Blood (2023) 141 (10): 1159–1168.

https://doi.org/10.1182/blood.2022016862

Published: 2023

Includes: Supplemental data

Journal Articles

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 2): LBA-1.

https://doi.org/10.1182/blood-2021-154729

Published: 2021

Journal Articles

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Blood (2021) 138 (Supplement 1): 303.

https://doi.org/10.1182/blood-2021-146657

Published: 2021

Journal Articles

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Shinya Rai, Lisa M. Hess, Yongmei Chen, Lee Bowman, Paolo B. Abada, Heiko Konig, Richard A. Walgren, Yoshinori Tanizawa, Zhihong Cai, Masaomi Tajimi

Blood (2021) 138 (Supplement 1): 4523.

https://doi.org/10.1182/blood-2021-148265

Published: 2021

Journal Articles

Two -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemiatwo -Year Follow-up Data of Phase II Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Patients with Treatment-Naïve or Relapsed/Refractory Waldenström's Macroglobulinemia

Kenshi Suzuki, Naohiro Sekiguchi, Shinya Rai, Wataru Munakata, Hiroshi Handa, Hirohiko Shibayama, Tomoyuki Endo, Yasuhito Terui, Noriko Iwaki, Noriko Fukuhara, Hiro Tatetsu, Shinsuke Iida, Takayuki Ishikawa, Daisuke Iguchi, Koji Izutsu

Blood (2021) 138 (Supplement 1): 1352.

https://doi.org/10.1182/blood-2021-146744

Published: 2021

Journal Articles

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Peter Trask, Jaisson Bortolini, Shinya Rai, Antonio Salar, Miguel Canales, Dirk Klingbiel, Joana Parreira, Maud Deraet, Ekaterina Vorozheikina, Kai Hübel, Thomas Buchholz

Blood (2021) 138 (Supplement 1): 1345.

https://doi.org/10.1182/blood-2021-147911

Published: 2021

Journal Articles

Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

Akira Nishimura, MD, Kazuaki Yokoyama, MD PhD, Chika Yamagishi, MD, Toshihiko Imamura, MD PhD, Takuya Naruto, MD PhD, Tomohiro Morio, MD PhD, Yukie Tanaka, PhD, Akinori Kanai, PhD, Hirotaka Matsui, MD PhD, Naoko Higuchi, MD, Akiko Takada, MD, Haruna Okuno, MD, Shoji Saito, MD PhD, Shuhei Karakawa, MD PhD, Shogo Kobayashi, MD, Daisuke Hasegawa, MD PhD, Hiroyuki Fujisaki, MD PhD, Daiichiro Hasegawa, MD PhD, Kazutoshi Koike, MD PhD, Takashi Koike, MD, Shinya Rai, MD PhD, Katsutsugu Umeda, MD PhD, Hideki Sano, MD, Yujin Sekinaka, MD PhD, Atsushi Ogawa, MD PhD, Akitoshi Kinoshita, MD PhD, Norio Shiba, MD PhD, Mizuka Miki, MD, Fumihiko Kimura, MD PhD, Hideki Nakayama, MD, Yozo Nakazawa, MD PhD, Takashi Taga, MD PhD, Tomohiko Taki, MD PhD, Souichi Adachi, MD PhD, Atsushi Manabe, MD PhD, Katsuyoshi Koh, MD, Yasushi Ishida, MD PhD, Arinobu Tojo, MD PhD, Masatoshi Takagi, MD PhD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-139312

Published: 2020

Journal Articles

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Shinya Rai, MD PhD, Koji Kato, MD PhD, Junji Suzumiya, MD PhD, Koji Izutsu, MD PhD, Momoko Nishikori, MD PhD, Hirohiko Shibayama, MD PhD, Yoshinobu Maeda, MD PhD, Kenichi Yoshimura, PhD, Ukihide Tateishi, MD PhD, Toshihiro Miyamoto, MD PhD, Jun Ishikawa, MD PhD, Tsutomu Takahashi, MD PhD, Takahiro Yamauchi, MD PhD, Koichi Akashi, MD PhD, Yuzuru Kanakura, MD PhD

Blood (2019) 134 (Supplement_1): 5245.

https://doi.org/10.1182/blood-2019-126455

Published: 2019

Journal Articles

Chlorpromazine, an Inhibitor of Intracellular Trafficking of FLT3-ITD and KIT D816V, Shows Prominent Anti-Leukemic Activities Against AML Cells and AML Stem Cells in Vitro and in Vivo.

Shinya Rai, MD, Hirokazu Tanaka, MD, PhD, Mai Suzuki, PhD, Akira Tanimura, Keiko Matsui, MD, PhD, Toshio Watanabe, PhD, Yuzuru Kanakura, MD PhD, Itaru Matsumura

Blood (2014) 124 (21): 269.

https://doi.org/10.1182/blood.V124.21.269.269

Published: 2014

NARROW

Randomized Phase III Study of Watchful Waiting Vs. Rituximab As First-Line Treatment in Patients with Advanced Stage Low Tumor Burden Follicular Lymphoma: JCOG1411/Flora Study

Tumor Microenvironment Differences between Diagnostic and Relapsed Classic Hodgkin Lymphoma Revealed By Single Cell Transcriptome Sequencing

Five-Year Analysis of the POLARIX Study: Prolonged Follow-up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes

CSF2RB Mutations Result in Cytokine-Dependent Gain-of-Function Phenotypes in Classic Hodgkin Lymphoma

Multiomic Profiling Reveals Pleiotropic Effects of Somatic IRF4-C99R Mutations in Primary Mediastinal Large B-Cell Lymphomas

A Multicenter, Prospective, Observational Study of Pola-R-CHP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (POLASTAR): A Preliminary Analysis

Genomic, Transcriptional, and Immunological Validation of Distinct Molecular Subtypes of Classic Hodgkin Lymphoma through Tissue-Based and Noninvasive Methods

Multi-Dimensional Molecular and Tumor-Microenvironment Analysis of Classic Hodgkin Lymphoma

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma

The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma

Outcomes for Patients with Mantle Cell Lymphoma Post-Covalent BTK Inhibitor Therapy in the United States and Japan: A Study of Two Real-World Databases

Obinutuzumab Short Duration Infusion Is Preferred By Healthcare Providers and Has Minimal Impact on Patient-Reported Symptoms Among Patients with Untreated, Advanced Follicular Lymphoma

Comprehensive Genetic Analysis Revealed Myeloid/Natural Killer (NK) Cell Precursor Acute Leukemia As a Novel Distinctive Leukemia Entity

End-of-Treatment 18[F]-FDG PET Can Predict Progression-Free Survival in Patients Undergoing Bendamustine + Rituximab for First Relapsed/Recurrent Follicular Lymphoma: The Result of W- J H S NHL01 Study

Chlorpromazine, an Inhibitor of Intracellular Trafficking of FLT3-ITD and KIT D816V, Shows Prominent Anti-Leukemic Activities Against AML Cells and AML Stem Cells in Vitro and in Vivo.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only